These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 22421587)

  • 1. Rituximab and multiple sclerosis.
    Kitsos DK; Tsiodras S; Stamboulis E; Voumvourakis KI
    Clin Neuropharmacol; 2012; 35(2):90-6. PubMed ID: 22421587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B-cell-targeted treatment for multiple sclerosis: mechanism of action and clinical data.
    Hawker K
    Curr Opin Neurol; 2008 Apr; 21 Suppl 1():S19-25. PubMed ID: 18388796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B cells as therapeutic targets in autoimmune neurological disorders.
    Dalakas MC
    Nat Clin Pract Neurol; 2008 Oct; 4(10):557-67. PubMed ID: 18813230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoimmune disease: A role for new anti-viral therapies?
    Dreyfus DH
    Autoimmun Rev; 2011 Dec; 11(2):88-97. PubMed ID: 21871974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodies.
    Gasperini C; Haggiag S; Ruggieri S
    Expert Opin Investig Drugs; 2013 Oct; 22(10):1243-53. PubMed ID: 23855792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. More to come: humoral immune responses in MS.
    Dobson R; Meier UC; Giovannoni G
    J Neuroimmunol; 2011 Dec; 240-241():13-21. PubMed ID: 22019113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibodies against CD20 (rituximab) for treating multiple sclerosis: US20100233121.
    Taupin P
    Expert Opin Ther Pat; 2011 Jan; 21(1):111-4. PubMed ID: 21155688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab levels in cerebrospinal fluid of patients with neurological autoimmune disorders.
    Petereit HF; Rubbert-Roth A
    Mult Scler; 2009 Feb; 15(2):189-92. PubMed ID: 18971221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebral rituximab uptake in multiple sclerosis: A
    Hagens MH; Killestein J; Yaqub MM; van Dongen GA; Lammertsma AA; Barkhof F; van Berckel BN
    Mult Scler; 2018 Apr; 24(4):543-545. PubMed ID: 28443358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of the current use of rituximab in autoimmune diseases.
    Gürcan HM; Keskin DB; Stern JN; Nitzberg MA; Shekhani H; Ahmed AR
    Int Immunopharmacol; 2009 Jan; 9(1):10-25. PubMed ID: 19000786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD16+ gammadelta T cells mediate antibody dependent cellular cytotoxicity: potential mechanism in the pathogenesis of multiple sclerosis.
    Chen Z; Freedman MS
    Clin Immunol; 2008 Aug; 128(2):219-27. PubMed ID: 18501678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B cells in multiple sclerosis therapy-A comprehensive review.
    Rahmanzadeh R; Weber MS; Brück W; Navardi S; Sahraian MA
    Acta Neurol Scand; 2018 Jun; 137(6):544-556. PubMed ID: 29512131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New insight in the mechanism of action of rituximab: the interferon signature towards personalized medicine.
    Verweij CL; Vosslamber S
    Discov Med; 2011 Sep; 12(64):229-36. PubMed ID: 21955850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Depletion of B lymphocytes from cerebral perivascular spaces by rituximab.
    Martin Mdel P; Cravens PD; Winger R; Kieseier BC; Cepok S; Eagar TN; Zamvil SS; Weber MS; Frohman EM; Kleinschmidt-Demasters BK; Montine TJ; Hemmer B; Marra CM; Stüve O
    Arch Neurol; 2009 Aug; 66(8):1016-20. PubMed ID: 19667224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relevance of rituximab therapy in pemphigus vulgaris: analysis of current data and the immunologic basis for its observed responses.
    Feldman RJ; Ahmed AR
    Expert Rev Clin Immunol; 2011 Jul; 7(4):529-41. PubMed ID: 21790294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab in a patient with multiple sclerosis--effect on B cells, plasma cells and intrathecal IgG synthesis.
    Petereit HF; Moeller-Hartmann W; Reske D; Rubbert A
    Acta Neurol Scand; 2008 Jun; 117(6):399-403. PubMed ID: 18031564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Basic mechanisms of action of fingolimod in relation to multiple sclerosis].
    García-Merino JA; Sánchez AJ
    Rev Neurol; 2012 Jul; 55(1):31-7. PubMed ID: 22718407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B-cell targeted therapies in human autoimmune diseases: an updated perspective.
    Townsend MJ; Monroe JG; Chan AC
    Immunol Rev; 2010 Sep; 237(1):264-83. PubMed ID: 20727041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bedside to bench: betting on B cells in multiple sclerosis.
    Link H
    Nat Med; 2008 Jun; 14(6):615-6. PubMed ID: 18535578
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis.
    Monson NL; Cravens PD; Frohman EM; Hawker K; Racke MK
    Arch Neurol; 2005 Feb; 62(2):258-64. PubMed ID: 15710854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.